Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Receivables (2016 - 2026)

Lexaria Bioscience's Change in Receivables history spans 12 years, with the latest figure at -$46015.0 for Q1 2026.

  • Quarterly results put Change in Receivables at -$46015.0 for Q1 2026, down 168.0% from a year ago — trailing twelve months through Feb 2026 was -$289136.0 (down 1491.72% YoY), and the annual figure for FY2025 was $213881.0, up 501.62%.
  • Change in Receivables for Q1 2026 was -$46015.0 at Lexaria Bioscience, up from -$280314.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $408045.0 in Q4 2023 to a low of -$280314.0 in Q4 2025.
  • The 5-year median for Change in Receivables is -$29500.0 (2023), against an average of -$21178.7.
  • The sharpest move saw Change in Receivables skyrocketed 382.68% in 2023, then crashed 1660.55% in 2024.
  • Year by year, Change in Receivables stood at $84538.0 in 2022, then skyrocketed by 382.68% to $408045.0 in 2023, then crashed by 73.28% to $109014.0 in 2024, then tumbled by 357.14% to -$280314.0 in 2025, then skyrocketed by 83.58% to -$46015.0 in 2026.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$46015.0, -$280314.0, and $10229.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.